Tumor necrosis factor-α blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?

Blocking tumor necrosis factor-α either with monoclonal antibodies or with soluble receptor constructs has been proven to be effective with an acceptable safety profile in patients with rheumatoid arthritis, and more recently also in the diseases belonging to the spondyloarthropathy concept. Neverth...

Descripción completa

Detalles Bibliográficos
Autores principales: Van den Bosch, Filip, De Keyser, Filip, Mielants, Herman, Veys, Eric M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1174966/
https://www.ncbi.nlm.nih.gov/pubmed/15899063
http://dx.doi.org/10.1186/ar1742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1174966/
https://www.ncbi.nlm.nih.gov/pubmed/15899063
http://dx.doi.org/10.1186/ar1742

Ejemplares similares